Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Purpose: The Ras-Raf-mitogen-activated protein kinase kinase (MEK) pathway is overactive in many human cancers and is thus a target for novel therapeutics. We have developed a highly potent and selective inhibitor of MEK1/2. The purpose of these studies has been to show the biological efficacy of ARRY-142886 (AZD6244) in enzymatic, cellular, and animal models. Experimental Design: The ability of ARRY-142886 to inhibit purified MEK1 as well as other kinases was evaluated. Its effects on extracellular signal-regulated kinase (ERK) phosphorylation and proliferation in several cell lines were also determined. Finally, the inhibitor was tested in HT-29 (colorectal) and BxPC3 (pancreatic) xenograft tumor models. Results: The IC50 of ARRY-142886 was determined to be 14 nmol/L against purified MEK1. This activity is not competitive with ATP, which is consistent with the high specificity of compound for MEK1/2. Basal and epidermal growth factor–induced ERK1/2 phosphorylation was inhibited in several cell lines as well as 12-O-tetradecanoylphorbol-13-acetate–induced ERK1/2 phosphorylation in isolated peripheral blood mononuclear cells. Treatment with ARRY-142886 resulted in the growth inhibition of several cell lines containing B-Raf and Ras mutations but had no effect on a normal fibroblast cell line. When dosed orally, ARRY-142886 was capable of inhibiting both ERK1/2 phosphorylation and growth of HT-29 xenograft tumors in nude mice. Tumor regressions were also seen in a BxPC3 xenograft model. In addition, tumors remained responsive to growth inhibition after a 7-day dosing holiday. Conclusions: ARRY-142886 is a potent and selective MEK1/2 inhibitor that is highly active in both in vitro and in vivo tumor models. This compound is currently being investigated in clinical studies.

[1]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[2]  S. Kimura,et al.  The MEK1‐ERK MAP kinase pathway and the PI 3‐kinase‐Akt pathway independently mediate anti‐apoptotic signals in HepG2 liver cancer cells , 2001, International journal of cancer.

[3]  Channing J Der,et al.  Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? , 2004, Trends in cell biology.

[4]  R. Marais,et al.  The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.

[5]  A. Porter,et al.  Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis , 1998, Oncogene.

[6]  N. Ahn,et al.  Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1. , 1996, Biochemistry.

[7]  M. Beeram,et al.  Raf: a strategic target for therapeutic development against cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. LoRusso,et al.  Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[10]  K. Resing,et al.  Pharmacologic inhibitors of MKK1 and MKK2. , 2001, Methods in enzymology.

[11]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[12]  M. Garnett,et al.  Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. , 2005, Cancer research.

[13]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[14]  W. R. Bishop,et al.  Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. , 2002, Experimental cell research.

[15]  A. Adjei,et al.  K-ras as a target for cancer therapy. , 2005, Biochimica et biophysica acta.

[16]  Alan R. Saltiel,et al.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo , 1999, Nature Medicine.

[17]  W. Park,et al.  Mutational analysis of the ARAF gene in human cancers , 2005, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  Donoghue,et al.  RTK mutations and human syndromes: when good receptors turn bad , 2000, Trends in genetics : TIG.

[19]  Tian-Li Wang,et al.  Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. , 2005, Cancer research.

[20]  J. Blenis,et al.  Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[21]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[22]  S. Cartlidge,et al.  368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor , 2004 .

[23]  J. Lyssikatos,et al.  342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model , 2004 .

[24]  G. Woude,et al.  Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Salgia,et al.  Therapeutic targeting of receptor tyrosine kinases in lung cancer , 2005, Expert opinion on therapeutic targets.

[26]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[27]  E. Estey,et al.  Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. , 2001, The Journal of clinical investigation.

[28]  M. Kohno,et al.  Blockade of the Extracellular Signal-regulated Kinase Pathway Induces Marked G1 Cell Cycle Arrest and Apoptosis in Tumor Cells in Which the Pathway Is Constitutively Activated , 2001, The Journal of Biological Chemistry.

[29]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[30]  J. Hecht,et al.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  P. LoRusso,et al.  A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer , 2005 .

[32]  K. Fransén,et al.  Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.